Qiming U.S. Healthcare Fund II, L.P. - Jun 24, 2021 Form 3 Insider Report for Elevation Oncology, Inc. (ELEV)

Role
10%+ Owner
Signature
Qiming U.S. Healthcare Fund II, L.P., by Qiming U.S. Healthcare GP II, LLC, its General Partner
Stock symbol
ELEV
Transactions as of
Jun 24, 2021
Transactions value $
$0
Form type
3
Date filed
6/24/2021, 06:16 PM
Next filing
Jul 1, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ELEV Series A Preferred Stock Jun 24, 2021 Common Stock 1.66M Direct F1, F2
holding ELEV Series B Preferred Stock Jun 24, 2021 Common Stock 401K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares of the Issuer's Preferred Stock will automatically convert on a 4.225582-for-one basis into the number of shares of the issuer's Common Stock shown in column 3 immediately upon the closing of the issuer's initial public offering, and has no expiration date.
F2 The securities are directly held by Qiming U.S. Healthcare Fund II, L.P. ("Qiming"). Qiming U.S. Healthcare GP II, LLC ("Qiming GP") is the General Partner of Qiming, and may deem beneficial ownership of shares held by Qiming, and includes Gary Rieschel, as Managing Member of Qiming GP, and Mark McDade, Co-Founder, and Partner of Qiming, that each may share voting and investment power of the shares held by Qiming.